Plain-English translation of NCT05514327 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new combination approach for people with diffuse large B cell lymphoma (a serious blood cancer) that has come back or stopped responding to standard chemotherapy. The study combines two treatments: radiation therapy targeting the cancer and CAR-T cell therapy, which uses your own immune cells that have been specially engineered to fight the cancer. Researchers want to see if giving radiation first, followed by the cell therapy, is safe and effective.
Many people with this type of advanced lymphoma don't respond well to standard chemotherapy alone, and others can't receive a stem cell transplant, which is the typical next step. This trial is exploring whether combining radiation with CAR-T cell therapy might offer these patients a better option.
You likely qualify if…
You likely don't qualify if…
You would receive radiation therapy treatments first, designed to target your cancer with very small, frequent doses. After this bridging radiation, you would receive CAR-T cell therapy, which involves infusing specially engineered cells into your body to fight the cancer. The study will monitor you closely for safety and effectiveness, tracking how well the treatment works and any side effects you experience.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Sponsor
Peking Union Medical College Hospital
Enrollment target
~20 participants
Started
September 2022
Primary completion
September 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jing Ruan, Docter
Peking Union Medical College Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.